Cargando…

The impact of venetoclax based regimens in the preemptive of measurable residual disease in acute myeloid leukemia

Detalles Bibliográficos
Autores principales:	Fang, Qiuyun, Gong, Xiaoyuan, Li, Yan, Gong, Benfa, Liu, Yuntao, Liu, Kaiqi, Zhang, Guangji, Wei, Shuning, Lin, Dong, Liu, Bingcheng, Wang, Ying, Wei, Hui, Mi, Yingchang, Wang, Jianxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975090/ https://www.ncbi.nlm.nih.gov/pubmed/35399543 http://dx.doi.org/10.1097/BS9.0000000000000101

Ejemplares similares

Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified
por: Liu, Kaiqi, et al.
Publicado: (2021)

Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population
por: Wei, Hui, et al.
Publicado: (2018)

Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia
por: Wei, Hui, et al.
Publicado: (2020)

The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia
por: Gu, Runxia, et al.
Publicado: (2017)

An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification
por: Qiu, Shaowei, et al.
Publicado: (2017)

Gene Deletions and Prognostic Values in B-Linage Acute Lymphoblastic Leukemia
por: Fang, Qiuyun, et al.
Publicado: (2021)

Candidemia in Patients with Acute Leukemia: Analysis of 7 Years’ Experience at a Single Center in China
por: Gong, Xiaoyuan, et al.
Publicado: (2020)

The clinical characteristics and prognosis in adult Ph negative acute lymphoblastic leukemia with TP53 aberrations
por: Fang, Qiuyun, et al.
Publicado: (2022)

Chimeric antigen receptor-modified T-cell therapy for bone marrow and skin relapse Philadelphia chromosome-like acute lymphoblastic leukemia: A case report
por: Yang, Mianzeng, et al.
Publicado: (2020)

High-Dose Cytarabine in Acute Myeloid Leukemia Treatment: A Systematic Review and Meta-Analysis
por: Li, Wei, et al.
Publicado: (2014)

Treatment of STAT5b-RARA positive acute promyelocytic leukemia by Venetoclax combining with homoharringtonine, cytarabine: A case report and literature review
por: Zhang, Guangji, et al.
Publicado: (2022)

Venetoclax-containing regimens in acute myeloid leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2021)

Mature plasmacytoid dendritic cells associated with acute myeloid leukemia show similar genetic mutations and expression profiles to leukemia cells
por: Gong, Xiaoyuan, et al.
Publicado: (2022)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

Effects of genetic polymorphisms on methotrexate levels and toxicity in Chinese patients with acute lymphoblastic leukemia
por: Hao, Qishan, et al.
Publicado: (2022)

Comparison of multi-omics results between patients with acute myeloid leukemia with long-term survival and healthy controls
por: Song, Yang, et al.
Publicado: (2022)

How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia
por: Maiti, Abhishek, et al.
Publicado: (2022)

Auer rods in mixed phenotype acute leukemia, T/myeloid: A report of three cases
por: Li, Yan, et al.
Publicado: (2021)

Reduced ABO blood group antibody titers in patients after CD19 CAR-T cell therapy
por: Li, Qiang, et al.
Publicado: (2022)

PB1840: MONOCENTRIC EXPERIENCE OF VENETOCLAX-BASED REGIMENS FOR ACUTE MYELOID LEUKEMIA
por: Sciumè, M., et al.
Publicado: (2022)

Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia
por: Sciumè, Mariarita, et al.
Publicado: (2023)

Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia
por: Feng, Juan, et al.
Publicado: (2017)

Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
por: Maiti, Abhishek, et al.
Publicado: (2020)

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
por: Gu, Runxia, et al.
Publicado: (2020)

Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Fan, Shuang, et al.
Publicado: (2022)

Heterogeneity analysis of the CEBPAdm AML based on bZIP region mutations
por: Hui, Yan, et al.
Publicado: (2023)

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
por: Pratz, Keith W., et al.
Publicado: (2022)

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
por: Thompson, Meghan C., et al.
Publicado: (2022)

Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine
por: Ong, Shin Yeu, et al.
Publicado: (2022)

Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial
por: Suo, Xiaohui, et al.
Publicado: (2023)

Combined venetoclax and alvocidib in acute myeloid leukemia
por: Bogenberger, James, et al.
Publicado: (2017)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
por: Yuan, Linyu, et al.
Publicado: (2023)

Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens
por: Jensen, Christopher E., et al.
Publicado: (2022)

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
por: Griffioen, Mila S., et al.
Publicado: (2022)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
por: Gutman, Jonathan A., et al.
Publicado: (2023)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
por: Gong, Xubo, et al.
Publicado: (2023)

Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms
por: Yuan, Fangfang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d73mkpv06bvjonn8jtdvk2o48t